Summary
This Form 8-K/A filing from Bristol-Myers Squibb (BMY) serves as an amendment to a previous 8-K filing dated April 27, 2006. The primary purpose of this amendment is to provide revised supplemental financial information for the first quarter of 2006, as of March 31, 2006. This updated information includes net sales, inventory levels (months on hand), and estimated demand for key products and growth drivers across its International Pharmaceutical, Nutritionals, and Other Health Care segments.
Key Highlights
- 1Amendment to prior 8-K filing to update financial disclosures.
- 2Revised supplemental financial information provided for Q1 2006.
- 3Information includes net sales, months on hand (inventory), and estimated demand.
- 4Data is broken down by International Pharmaceutical, Nutritionals, and Other Health Care segments.
- 5Net sales and inventory data is also provided for comparison as of December 31, 2005, and March 31, 2005.
- 6The revised supplemental information is attached as Exhibit 99.2.
Frequently Asked Questions
This filing is an amendment to a previous 8-K. It provides updated and revised supplemental financial information for Bristol-Myers Squibb's first quarter of 2006, specifically relating to net sales, inventory levels, and estimated product demand.
The revised supplemental information includes net sales, 'months on hand' (which typically refers to inventory levels), and estimated demand for key products and growth drivers. This data is presented for the first quarter of 2006, with comparative data from the end of 2005 and the first quarter of 2005.
The revised supplemental information covers the Company's International Pharmaceutical, Nutritionals, and Other Health Care reporting segments.
The revised supplemental information is furnished and incorporated by reference as Exhibit 99.2 to this Form 8-K/A, and was also posted on the Company's website at www.bms.com.